Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Construction in Progress (2021 - 2023)

Arrowhead Pharmaceuticals (ARWR) has disclosed Construction in Progress for 3 consecutive years, with $166.7 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Construction in Progress rose 195.63% year-over-year to $166.7 million, compared with a TTM value of $166.7 million through Sep 2023, up 195.63%, and an annual FY2023 reading of $166.7 million, up 195.63% over the prior year.
  • Construction in Progress was $166.7 million for Q3 2023 at Arrowhead Pharmaceuticals, up from $118.3 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $166.7 million in Q3 2023 and bottomed at $345000.0 in Q3 2021.
  • Average Construction in Progress over 3 years is $65.6 million, with a median of $56.4 million recorded in 2022.
  • The sharpest move saw Construction in Progress soared 16240.0% in 2022, then surged 195.63% in 2023.
  • Year by year, Construction in Progress stood at $2.2 million in 2021, then skyrocketed by 4092.15% to $90.2 million in 2022, then soared by 84.73% to $166.7 million in 2023.
  • Business Quant data shows Construction in Progress for ARWR at $166.7 million in Q3 2023, $118.3 million in Q2 2023, and $127.2 million in Q1 2023.